須田 剛生

須田 剛生

特任助教

学歴

1993年3月
桐朋学園高校卒業
2000年3月
信州大学医学部医学科卒業
2012年3月
東京医科歯科大学大学院医学博士課程修了

職経

2000年4月
東京医科歯科大学病院研修医
2001年6月
北信総合病院消化器内科 医員
2004年6月
土浦協同病院消化器内科 医員
2006年4月
東京医科歯科大学消化器内科 医員
2010年4月
取手総合病院消化器内科 医員
2012年9月
北海道大学消化器内科 特任助教

専門分野

  • 肝臓病診断・治療
  • ウイルス性肝炎

所属学会・資格

  • 日本内科学会 認定内科医
  • 日本消化器病学会 専門医
  • 日本消化器内視鏡学会 専門医
  • 日本肝臓学会 専門医・東部会評議員

趣味

サーフィン,ランニング

好きな言葉

意志あるところに道あり

受賞歴

  • 2011年 国際科学振興財団フォーラム研究奨励賞受賞
  • 2015年 Liver Forum in Kyoto 研究奨励賞
  • 2016年 肝臓病学会研究奨励症

研究費等

厚生労働省科学研究費補助金/日本医療研究開発機構(AMED)
  • 肝炎等克服実用化研究事業 「次世代シークエンス技術を駆使したウイルスゲノム解析によるC型肝炎の病態解明と臨床応用」研究分担者(2013年度-2015年度)
  • 肝炎等克服実用化研究事業 「次世代シークエンス技術によるウイルス因子解析を基軸としたC型肝炎新規治療の病態解明と臨床応用」研究分担者(2016年度-2018年度)
  • 肝炎等克服実用化研究事業 「C型肝炎の新たな治療関連因子及び治癒後の病態進展・改善に関連する宿主因子等の同定を目指したゲノムワイド研究」研究分担者(2016年度-2018年度)
  • 肝炎等克服実用化研究事業 「C型肝炎のウイルス排除後に起こる病態に関する研究」研究分担者(2017年度-2019年度)
文部科学省科学研究費補助金
  • 基盤研究(C) 「C末端欠損HBx遺伝子インテグレーションによる肝発癌・悪性化機構の検討」研究代表者 (2016年度―2018年度)
  • 基盤研究(C) 「HCVに対するカルニチンの抗ウイルス/抗脂肪化/抗酸化効果の基礎的・臨床的検討」研究分担者(2015年度-2017年度)
  • 萌芽研究 「高速分子動力学法によるHCV抗ウイルス薬耐性化予測仮想アッセイシステムの構築」研究研究分担者(2014年度-2015年度)
  • 若手研究(B) 「HCVキメラウイルス感染培養系を用いた薬剤耐性機序の解析」研究代表者(2013年度-2014年度)

論文(英文のみ)

  1. Goki Suda#, Norihiro Furusyo#, Hidenori Toyoda#, Yoshiiku Kawakami#, Hiroki Ikeda, Michihiro Suzuki, Keiko Arataki, Nami Mori, Keiji Tsuji, Yoshio Katamura, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Noritomo Shimada, Atsushi Hiraoka, Sho Yamsaki, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Mineo Kudo, Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto, Kanji Kato ,Yoshiyuki Ueno, Etsuko Iio, Yasuhito Tanaka, Masayuki Kurosaki, Takashi Kumada, Kazuaki Chayama and Naoya Sakamoto.
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2017 (in press).
  2. Naoki Kawagishi*, Goki Suda*, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto (*Equal contribution).
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis.
    Journal of Viral Hepatitis. 2017 (in press).
  3. Takuya Sho, Mitsuru Nakanishi, Morikawa Kenichi, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Goki Suda, Koji Ogawa, Makoto Chuma, Takashi Meguro, Michio Nakamura, Atsushi Nagasaka, Hiromasa Horimoto, Yoshiya Yamamoto, and Naoya Sakamoto.
    A Phase I study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma.
    Drugs in R&D. 2017 (in press).
  4. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N (Equal contribution).
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 22. pii: S0168-8278(17)30249-0. doi: 10.1016/j.jhep.2017.04.008. [Epub ahead of print]
  5. Takahiko Kobayashi, Junich Ishida, Yuichi Shimizu,Hiroshi Kawakami, Goki Suda, Tetsuhito Muranaka, Yoshito Komatsu, Masahiro Asaka and Naoya Sakamoto N.
    Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer.
    Tumor Biology. March 2017: 1-9.
  6. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017 Mar 18. doi: 10.1007/s00535-017-1328-z. [Epub ahead of print]
  7. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327. doi: 10.14218/JCTH.2016.00032. Review.
  8. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment.
    Hepatol Res. 2016 Dec 12. doi: 10.1111/hepr.12851.
  9. Tsukuda Y, Suda G*, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto.
    (*Corresponding author ) Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24692 (in press).
  10. Tsunematsu S, Suda G*, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    (*Corresponding author).
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb;89(2):267-275. doi: 10.1002/jmv.24643.
  11. Seiji Tsunematsu, Goki Suda,* Kazushi Yamasaki, Megumi Kimura, Izumi Takaaki, Machiko Umemura, Jun Ito, Fumiyuki Sato, Masato Nakai, Takuya Sho,Kenichi Morikawa, Koji Ogawa, Toshiya Kamiyama, Akinobu Taketomi and Naoya Sakamoto (*Corresponding author ).
    Combination of neutrophil-to-lymphocyte ratio and early des-gamma-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2016 (in press).
  12. Jun Ito, Goki Suda*, Yoshiya Yamamoto, Atsushi Nagasaka, Ken Furuya, Kenichi Kumagai, Hideaki Kikuchi, Takuto Miyagishima, Tomoe Kobayashi, Megumi Kimura, Kazushi Yamasaki, Machiko Umemur, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi Terashita, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto (* Corresponding author).
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Dec;46(13):1294-1303. doi: 10.1111/hepr.12685.
  13. Morikawa K, Suda G, Sakamoto N.
    Viral life cycle of hepatitis B virus : host factors and druggable targets.
    Hepatol Res. 2016 Aug;46(9):871-7.
  14. Goki Suda, Mineo Kudo , Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto, Tomoe Kobayashi, Keisuke Shinada, Miki Tateyama, Jun Konno, Yoko Tsukuda, Kazushi Yamasaki, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Katsumi Terasita, Masato Nakai, Hiromasa Horimoto, Takuya Sho, Mitsuteru Natsuizka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto.
    Efficacy and safety of daclatasvir and asnaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis.
    J Gastroenterol. 2016 Jul;51(7):733-40. doi: 10.1007/s00535-016-1162-8.
  15. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 2015;16(10):1453-61. doi: 10.1080/15384047.2015.1070992.
  16. Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, Komatsu Y, Ohashi S, Kagawa S, Kinugasa H, Whelan KA, Rustgi AK, Nakagawa H, Sakamoto N.
     EGFR inhibitors eliminate cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Cancer Biology & Therapy. 2015 (in press).
  17. Onishi R, Ohnishi S, Higashi R, Watari M, Yamahara K, Okubo N, Nakagawa K, Katsurada T, Suda G, Natsuizaka M, Takeda H, Sakamoto N.
    Human amnion-derived mesenchymeal stem cell transplantation ameliorates dextran sulfate sodium-induced severe colitis in rats.
    Cell Transplantation. 2015 (in press).
  18. Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 2015 (in press).
  19. Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, Tsunematsu S, Sato F, Terasita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Fujita Y, Abe R, Taniguchi M, Nakagawa M, Asahina Y, Sakamoto N; NORTE Study Group.
    Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.
    Hepatology Res. 2015 (in press) doi: 10.1111/hepr.12421.
  20. Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi M, Natsuizaka M, Suda G, Sho T, Hatanaka K, Matsuno Y, Yokoo H, Kamiyama T, Taketomi A, Fujii G, Tashiro K, Hikiba Y, Fujimoto M, Asaka M, Maeda S.
    Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor κB/mitogen-activated protein kinase.
    Carcinogenesis. 2014;35(2):272-81 doi: 10.1093/carcin/bgt343.
  21. Tsunematsu S, Natsuizaka M, Fujita H, Otsuka N, Terashita K, Sato F, Kobayashi T, Nakai M, Tsukuda Y, Horimoto H, Sho T, Suda G, Nakanishi M, Hashino S, Chuma M, Sakamoto N.
    Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein Barr Virus.
    Intern Med. 2014; 53(18):2079-82.
  22. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, Watanabe T, Mishima K, Ueyama M, Onozuka I, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M.
    .Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.
    J Virol. 2011; 5986-94.
  23. Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Watanabe M.
    IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.
    Virology. 2010; 407:80-90.
  24. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M.
    Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
    J Gastroentorol. 2010; 45(5):523-536.
  25. Itsui Y, Sakamoto N, Kakinuma S, Nakagawa M, Sekine-Osajima Y, Tasaka-Fujita M, Nishimura-Sakurai Y, Suda G, Karakama Y, Mishima K, Yamamoto M, Watanabe T, Ueyama M, Funaoka Y, Azuma S, Watanabe M.
    Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein.
    Hepatology. 2009; 50:1727-1737.
  26. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen CH, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, Kanai T, Tsuchiya K, Watanabe M.
    Two flavonoids extracts from a herb, Glycyrrhizae radix, inhibit in-vitro hepatitis C virus replication.
    Hepatology Res. 2009; 39(1): 60-69.